Coherus BioSciences
Coherus BioSciences's Overview
Coherus BioSciences (NASDAQ: CHRS) is a commercial-stage biopharmaceutical company committed to an innovative business model focused on bringing high-quality biosimilar and novel oncology and immunology therapeutics to patients. Their mission is to increase patient access to important, cost-effective medicines. Coherus has successfully launched multiple products in the U.S. market, including biosimilars for supportive care in oncology and an immuno-oncology therapy. The company is also advancing a pipeline of proprietary and partnered novel therapeutics.
Where is Coherus BioSciences's Headquarters?
HQ Function
Serves as the central hub for corporate leadership, strategic planning, research and development oversight, commercial operations, and administrative functions.
Notable Features:
Modern office facilities located in a prominent San Francisco Bay Area biotechnology cluster, designed to support collaboration and innovation.
Work Culture:
Coherus fosters an entrepreneurial, results-oriented, and collaborative environment. The culture emphasizes scientific rigor, patient-centricity, integrity, and agility in navigating the dynamic biopharmaceutical landscape.
HQ Significance:
The headquarters is pivotal for Coherus's strategic decision-making, coordination of global clinical trials, product development, and commercialization efforts in the U.S. market.
Values Reflected in HQ: The headquarters' environment aims to reflect Coherus's core values of innovation, collaboration, excellence, and a commitment to improving patient lives through accessible medicines.
Location:
Coherus BioSciences' commercial operations are primarily focused on the United States market. However, the company engages in global activities for research, clinical development, and strategic partnerships to advance its pipeline. Clinical trials for its products often involve international sites. While direct commercial presence is U.S.-centric, its collaborations and development efforts have a global reach.
Street Address:
333 Twin Dolphin Drive, Suite 600
City:
Redwood City
State/Province:
CA
Country:
USA
Coherus BioSciences's Global Presence
Camarillo, CA, USA
Address: 500 Patriot Way, Camarillo, CA 93012
Enhances Coherus's internal manufacturing capacity and control over its supply chain for key biologic drug candidates, primarily supporting U.S. operations and development.
Buying Intent Signals for Coherus BioSciences
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Coherus BioSciences
As of April 2025, Coherus BioSciences' leadership includes:
Investors of Coherus BioSciences
Coherus BioSciences has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Coherus BioSciences has seen several key leadership changes over the past year, strengthening its executive team with new appointments in medical, financial, and legal roles, alongside some notable departures.
Departures
New Appointments:
Technology (Tech Stack) used by Coherus BioSciences
Discover the tools Coherus BioSciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Coherus BioSciences Email Formats and Examples
Coherus BioSciences commonly utilizes standard corporate email formats. The most prevalent format is typically the first initial followed by the last name.
flast@coherus.com
Format
jdoe@coherus.com
Example
90%
Success rate
News and media
Coherus BioSciences Press Release • June 3, 2024
Coherus BioSciences news title: Coherus Presents New Analysis of TORIPALIMAB Data Demonstrating Clinically Meaningful Overall Survival Benefit in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma at ASCO 2024
Coherus BioSciences announced new, late-breaking data from a sub-analysis of the JUPITER-02 Phase 3 study, further supporting the clinically meaningful overall survival benefit of LOQTORZI™ (toripalimab-tpzi) in combination with chemotherapy compared to chemotherapy alone as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)....more
Coherus BioSciences Press Release • May 8, 2024
Coherus BioSciences news title: Coherus BioSciences Reports First Quarter 2024 Financial Results and Recent Business Highlights
Coherus reported total net product revenue of $76.7 million for Q1 2024, driven by UDENYCA® sales and the launch of LOQTORZI™. The company highlighted progress in its oncology franchise and ongoing efforts to manage expenses and drive towards profitability....more
Coherus BioSciences Press Release • December 26, 2023
Coherus BioSciences news title: Coherus Announces U.S. FDA Approval of UDENYCA ONBODY™ for Patients with Cancer Receiving Myelosuppressive Chemotherapy
Coherus announced that the U.S. FDA approved UDENYCA ONBODY™, its on-body injector presentation of UDENYCA® (pegfilgrastim-cbqv). This provides an alternative administration option for patients, enhancing convenience and potentially improving adherence....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Coherus BioSciences, are just a search away.